Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 Février 2024 - 2:00PM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of therapeutic
biologics to selectively modulate disease-specific T cells,
announced today that it will present at the Oppenheimer 34th Annual
Healthcare Life Sciences Conference being held virtually from
February 13-14, 2024.
During the presentation, Cue Biopharma’s chief
executive officer, Dan Passeri, will provide a corporate update
highlighting the latest developments from its lead clinical
programs, CUE-101 and CUE-102, its lead preclinical autoimmune
program partnered with Ono Pharmaceutical, as well as market
opportunities, competitive positioning and key forecasted
value-driving 2024 milestones.Presentation
DetailsOppenheimer 34th Annual
Healthcare Life Sciences ConferenceDate and
Time: Tuesday, February 13, 9:20 a.m. ESTWebcast
Link:
https://wsw.com/webcast/oppenheimer33/cue/2534426Presenter: Daniel
Passeri, M.Sc., J.D., chief executive officer, Cue
Biopharma
A live and archived webcast of the presentation will be
available on the Events page in the Investors and Media section of
the Company’s website at www.cuebiopharma.com. The webcast
will be archived for 30 days.
About Cue BiopharmaCue Biopharma, a
clinical-stage biopharmaceutical company, is developing a novel
class of injectable biologics to selectively engage and modulate
disease-specific T cells directly within the patient’s body. The
company’s proprietary platform, Immuno-STAT™ (Selective Targeting
and Alteration of T cells) and biologics are designed to harness
the curative potential of the body’s intrinsic immune system
through the selective modulation of disease-specific T cells
without the adverse effects of broad systemic immune
modulation.
Headquartered in Boston, Massachusetts, we are led by an
experienced management team and independent Board of Directors with
deep expertise in immunology and immuno-oncology as well as the
design and clinical development of protein biologics.
For more information please
visit www.cuebiopharma.com and follow us on Twitter
and LinkedIn.
Investor Contact Marie Campinell Senior
Director, Corporate CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com
Media ContactJonathan PappasLifeSci
Communicationsjpappas@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Cue Biopharma (NASDAQ:CUE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024